In This Article:
Symrise (ETR:SY1) Full Year 2023 Results
Key Financial Results
-
Revenue: €4.73b (up 2.4% from FY 2022).
-
Net income: €340.5m (up 22% from FY 2022).
-
Profit margin: 7.2% (up from 6.1% in FY 2022). The increase in margin was driven by higher revenue.
-
EPS: €2.44 (up from €2.00 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Symrise EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.2%.
The primary driver behind last 12 months revenue was the Taste, Nutrition & Health segment contributing a total revenue of €2.98b (63% of total revenue). Notably, cost of sales worth €3.04b amounted to 64% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Sales & Marketing costs, amounting to €675.8m (50% of total expenses). Explore how SY1's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Chemicals industry in Germany.
Performance of the German Chemicals industry.
The company's shares are up 12% from a week ago.
Risk Analysis
Be aware that Symrise is showing 1 warning sign in our investment analysis that you should know about...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.